Pitolisant: A Review in Narcolepsy with or without Cataplexy
Sign Up to like & getrecommendations! Published in 2020 at "CNS Drugs"
DOI: 10.1007/s40263-020-00703-x
Abstract: Pitolisant (Wakix ® ), an orally available, first-in-class antagonist/inverse agonist of the histamine 3 receptor, is approved in the EU (as of March 2016) for the treatment of narcolepsy with or without cataplexy in adults… read more here.
Keywords: without cataplexy; pitolisant; treatment; narcolepsy without ... See more keywords
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
Sign Up to like & getrecommendations! Published in 2019 at "Sleep"
DOI: 10.1093/sleep/zsz252
Abstract: Abstract Objectives To evaluate the human abuse potential of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult… read more here.
Keywords: pitolisant; receptor antagonist; pitolisant selective; drug ... See more keywords
Pitolisant for Daytime Sleepiness in Obstructive Sleep Apnea Patients Refusing CPAP: A Randomized Trial.
Sign Up to like & getrecommendations! Published in 2020 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.201907-1284oc
Abstract: BACKGROUND Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. We aimed to evaluate the efficacy and safety of pitolisant, a selective histamine H3-receptor antagonist with wake-promoting effects, for treatment of… read more here.
Keywords: sleepiness; sleep apnea; daytime sleepiness; obstructive sleep ... See more keywords